Table 1 Demographic information and clinical characteristics.

From: The different impacts of pain-related negative emotion and trait negative emotion on brain function in patients with inflammatory bowel disease

Items

IBD(n = 98)

HC(n = 46)

P value

Age (years)

30.38 ± 8.8

27.95 ± 7.5

0.112 *

Gender (male/female)

73/25

34/12

0.941‡

Education (years)

14.09 ± 2.6

14.93 ± 2.2

0.061*

Disease (n)

 Crohn disease

64

–

 

 Ulcerative colitis

34

–

 

 Duration of disease (years)

5.00 ± 4.30

–

 

Medication (n)

 Conventional immunosuppressantsa

38

–

 

 Biologicsb

71

–

 

Previous surgery (n)

–

 

 Ileal resection

13

  

 Ostomy

2

–

 

 ESR (mm/h)

19.18 ± 19.23

–

 

 CRP (mg/L)

14.39 ± 23.22

–

 

 IBS-SSS score

206.15 ± 84.63

–

 

 GIQLI score

107.70 ± 23.73

128.20 ± 11.70

< 0.001†

  1. Values denote mean ± standard deviation or numbers of subjects.
  2. CRP C-reactive protein, ESR erythrocyte sedimentation rate, GIQLI gastrointestinal quality of life index, HC healthy control, IBD inflammatory bowel diseases; IBS-SSS irritable bowel syndrome severity scoring system.
  3. *Independent-samples t-tests.
  4. †Mann–Whitney U-tests.
  5. ‡chi-square test.
  6. P < 0.05 was considered significant.
  7. aIncludes corticosteroids, mesalazine, methotrexate, azathioprine, and 6-mercaptopurine.
  8. bInfliximab, adalimumab, ulinumab, vedrizumab.
Back to article page